Emmanuel Thomas

Research Assistant Professor

  • 1070 Citations
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Research interests

The mission of Dr. Thomas’s program is to develop integrated, multidisciplinary approaches to the study of liver cancer/liver diseases and to bridge clinical medicine and basic science with translation of fundamental knowledge to prevention, diagnosis, and treatment of liver diseases. Dr. Thomas is a Fellow of the American Association for the Study of Liver Diseases (FAASLD).  He serves on the National Advisory Board of the American Liver Foundation and he is on the editorial board of Hepatology.  Dr. Thomas currently has over $4million dollars in program support through the National Institutes of Health (NIH) and the Florida Department of Health (FL-DOH).

Since completing a Doris Duke Clinical Fellowship and graduating from the University of Miami Miller School of Medicine in May 2007 simultaneously obtaining both the MD and PhD degrees, Dr. Thomas has made steady progress toward creating and implementing a translational research program focused on preventing liver disease and hepatocellular carcinoma. Our program leverages resources and clinical/scientific expertise available through the Miami CTSI, the Schiff Center for Liver Diseases, the Sylvester Comprehensive Cancer Center and the Miami Center for AIDS Research to address the rapid development of liver disease and Hepatocellular Carcinoma which occurs in patients with viral hepatitis. Infection by the Hepatitis B and C viruses and HIV impacts our South Florida community significantly and our efforts will help minimize their detrimental effects in our catchment area.

Having been raised in Miami-Dade county, Dr. Thomas has a strong commitment to improving the health of our local community. Recently, breakthroughs have been achieved in the treatment of viral hepatitis and specifically for treatment of HCV. Potent all oral therapies are now available to cure patients with HCV infection. Through our community screening program, we are identifying HCV infected individuals and linking them to care so that they can be cured of this deadly virus. In addition, we are also facilitating the ability of uninsured patients to receive these costly medications through patient assistance programs.

External positions

FAASLD, American Association for the Study of Liver Diseases

National Board of Directors, American Liver Foundation

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 6 Similar Profiles
Interferons Medicine & Life Sciences
Hepacivirus Medicine & Life Sciences
Virus Diseases Medicine & Life Sciences
Hepatitis C Medicine & Life Sciences
Liver Medicine & Life Sciences
Ribavirin Medicine & Life Sciences
Liver Cirrhosis Medicine & Life Sciences
Innate Immunity Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2017 2022

Virus Diseases
Innate Immunity
Epithelial Cells
Interferon Type I

Research Output 2004 2019

  • 1070 Citations
  • 33 Article
  • 2 Comment/debate
  • 1 Editorial
2 Citations (Scopus)

17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease

(for the Nonalcoholic Steatohepatitis Clinical Research Network), Jan 1 2019, In : Hepatology.

Research output: Contribution to journalArticle

17-Hydroxysteroid Dehydrogenases
Single Nucleotide Polymorphism

Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey

Kasting, M. L., Giuliano, A. R., Reich, R. R., Roetzheim, R. G., Duong, L. M., Thomas, E., Nelson, D. R., Shenkman, E. & Vadaparampil, S. T., Jun 1 2019, In : Cancer Epidemiology. 60, p. 112-120 9 p.

Research output: Contribution to journalArticle

Open Access
Health Surveys
Liver Neoplasms

When parallel roads meet: Orchestrating collaborations between regulatory, ethical and business partners in translational medicine

Tabori, U., Ferenbok, J., Thomas, E., Swart, J. F., Albani, S., Seyfert-Margolis, V. L. & Sauvage, E. L., Jan 1 2019, In : Frontiers in Medicine. 6, APR, 87.

Research output: Contribution to journalComment/debate

Open Access
Translational Medical Research
2 Citations (Scopus)

Differentiation of hepatocyte-like cells from human pluripotent stem cells using small molecules

Asumda, F. Z., Hatzistergos, K. E., Dykxhoorn, D. M., Jakubski, S., Edwards, J., Thomas, E. & Schiff, E. R., May 1 2018, In : Differentiation. 101, p. 16-24 9 p.

Research output: Contribution to journalArticle

Pluripotent Stem Cells
Periodic Acid
Regenerative Medicine

Hepatitis B virus X protein: TRIMming antiviral defences in hepatocytes

Thomas, E., Jan 1 2018, In : Gut. 67, 1, p. 3-4 2 p.

Research output: Contribution to journalComment/debate

Virus Replication
Hepatitis B
Innate Immunity
Hepatitis B virus